[go: up one dir, main page]

MX2012014071A - Composicion farmaceutica estable para el tratamiento de osteoporosis. - Google Patents

Composicion farmaceutica estable para el tratamiento de osteoporosis.

Info

Publication number
MX2012014071A
MX2012014071A MX2012014071A MX2012014071A MX2012014071A MX 2012014071 A MX2012014071 A MX 2012014071A MX 2012014071 A MX2012014071 A MX 2012014071A MX 2012014071 A MX2012014071 A MX 2012014071A MX 2012014071 A MX2012014071 A MX 2012014071A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
stable pharmaceutical
treating osteoporosis
compositions
osteoporosis
Prior art date
Application number
MX2012014071A
Other languages
English (en)
Other versions
MX350569B (es
Inventor
María Del Lourdes García Mondragón
Alejandro Reyes Santiago
Original Assignee
Landsteiner Scient S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landsteiner Scient S A De C V filed Critical Landsteiner Scient S A De C V
Priority to MX2012014071A priority Critical patent/MX350569B/es
Priority to ES13859631.7T priority patent/ES2629739T3/es
Priority to PCT/MX2013/000130 priority patent/WO2014088385A1/es
Priority to EP13859631.7A priority patent/EP2926817B1/en
Priority to US14/647,981 priority patent/US20150342968A1/en
Priority to JP2015545408A priority patent/JP6374879B2/ja
Publication of MX2012014071A publication Critical patent/MX2012014071A/es
Publication of MX350569B publication Critical patent/MX350569B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas que aumentan la biodisponibilidad de risedronato de sodio, y proporciona Vitamina D3 con una mayor estabilidad, dichas composiciones son útiles para inhibir la resorción ósea.
MX2012014071A 2012-12-03 2012-12-03 Composicion farmaceutica estable para el tratamiento de osteoporosis. MX350569B (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2012014071A MX350569B (es) 2012-12-03 2012-12-03 Composicion farmaceutica estable para el tratamiento de osteoporosis.
ES13859631.7T ES2629739T3 (es) 2012-12-03 2013-10-30 Composición farmacéutica estable para el tratamiento de osteoporosis
PCT/MX2013/000130 WO2014088385A1 (es) 2012-12-03 2013-10-30 Composición farmacéutica estable para el tratamiento de osteoporosis
EP13859631.7A EP2926817B1 (en) 2012-12-03 2013-10-30 Stable pharmaceutical composition for treating osteoporosis
US14/647,981 US20150342968A1 (en) 2012-12-03 2013-10-30 Stable pharmaceutical composition for treating osteoporosis
JP2015545408A JP6374879B2 (ja) 2012-12-03 2013-10-30 骨粗しょう症治療用の安定な医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012014071A MX350569B (es) 2012-12-03 2012-12-03 Composicion farmaceutica estable para el tratamiento de osteoporosis.

Publications (2)

Publication Number Publication Date
MX2012014071A true MX2012014071A (es) 2014-06-23
MX350569B MX350569B (es) 2017-09-11

Family

ID=50883732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014071A MX350569B (es) 2012-12-03 2012-12-03 Composicion farmaceutica estable para el tratamiento de osteoporosis.

Country Status (6)

Country Link
US (1) US20150342968A1 (es)
EP (1) EP2926817B1 (es)
JP (1) JP6374879B2 (es)
ES (1) ES2629739T3 (es)
MX (1) MX350569B (es)
WO (1) WO2014088385A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2022056220A2 (en) * 2020-09-11 2022-03-17 Reform Biologics, Inc. Excipient compounds for protein formulations
CN119385959B (zh) * 2025-01-03 2025-04-01 山东第一医科大学附属省立医院(山东省立医院) 一种利塞膦酸钠片剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004807A (es) 2004-05-19 2005-11-24 Merck & Co Inc Composiciones y metodos para inhibir la resorcion osea.
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
KR100822133B1 (ko) 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
EP2127656A4 (en) * 2006-12-20 2010-03-03 Landsteiner Scient S A De C V COMPOSITIONS OF RISEDRONATE AND VITAMIN D3
KR100844256B1 (ko) * 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
EP2201937A1 (en) * 2008-12-23 2010-06-30 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin D or derivatives thereof
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
KR20120005228A (ko) * 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법

Also Published As

Publication number Publication date
JP6374879B2 (ja) 2018-08-15
WO2014088385A1 (es) 2014-06-12
EP2926817A1 (en) 2015-10-07
ES2629739T3 (es) 2017-08-14
EP2926817B1 (en) 2017-03-29
MX350569B (es) 2017-09-11
JP2016501226A (ja) 2016-01-18
EP2926817A4 (en) 2016-05-18
US20150342968A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
UY33735A (es) Compuestos antivirales
MD20150091A2 (ro) Compuşi antivirali
PH12016501151A1 (en) Nrf2 regulators
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
GEP20207102B (en) Sulfonamides as modulators of sodium channels
GEP20166438B (en) Imidazopyrrolidinone compounds
SG10201810879VA (en) Pharmaceutical compounds
IN2014DN10576A (es)
MY173521A (en) Trpv4 antagonists
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
PH12014502032A1 (en) Treatment of brain cancer
MX362879B (es) Usos novedosos.
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
IN2013MU03641A (es)
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX350569B (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
MX347541B (es) Analogos de acido sialico.
IN2014DN03010A (es)
UA110131C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
IN2014DN08294A (es)
MX338113B (es) Proceso para la preparacion de polisulfonato de sodio del 5,14-dihidrotetraazapentaceno e intermediarios de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration